Jeremy Skillington from Poolbeg Pharma explains the significance of the patent grant for POLB 002, a nasally administered treatment with the potential to protect against RSV infections.
Key things for a potential partner are the data set that's been generated and the intellectual property that surrounds the program, so we're happy to get this patent granted he says.
The RNA of the candidate interferes with the replication of a natural influenza virus so can be administered before infection and also after someone catches it, he adds.